Drug General Information
Drug ID
D0I0UE
Former ID
DNC000875
Drug Name
Lexipafant
Drug Type
Small molecular drug
Indication Nerve injury [ICD10:T14.4] Phase 2 [533596]
Structure
Download
2D MOL

3D MOL

Formula
C23H30N4O4S
Canonical SMILES
CCOC(=O)C(CC(C)C)N(C)S(=O)(=O)C1=CC=C(C=C1)CN2C(=NC3=C2<br />C=CN=C3)C
InChI
1S/C23H30N4O4S/c1-6-31-23(28)22(13-16(2)3)26(5)32(29,30)19-9-7-18(8-10-19)15-27-17(4)25-20-14-24-12-11-21(20)27/h7-12,14,16,22H,6,13,15H2,1-5H3/t22-/m0/s1
InChIKey
AQRXDPFOYJSPMP-QFIPXVFZSA-N
CAS Number
CAS 139133-26-9
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Platelet-activating factor receptor Target Info Modulator
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Staphylococcus aureus infection
NetPath Pathway IL5 Signaling Pathway
Leptin Signaling Pathway
Reactome Class A/1 (Rhodopsin-like receptors)
G alpha (q) signalling events
Interferon gamma signaling
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Small Ligand GPCRs
Interferon gamma signaling
GPCR ligand binding
GPCR downstream signaling
References
Ref 533596Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995 Oct;82(10):1414-20.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.